文献速递性腺与生殖内分泌

绝经激素治疗与心血管疾病:制剂、剂量与给药途径的作用

Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本小型综述概述绝经激素治疗(HT)与心血管疾病(CVD)风险,聚焦激素制剂、剂量与给药途径的作用。证据显示口服无对抗雌激素对脂蛋白、血糖、胰岛素及CVD风险有有利影响,但加用孕激素削弱脂质相关效应,微粒化孕酮削弱最小;经皮雌激素对凝血、炎症和血脂影响小于口服,观察性研究提示其静脉血栓栓塞和卒中风险低于口服。HT不推荐用于CVD一级或二级预防。

要点

  • 口服无对抗雌激素改善脂蛋白、血糖、胰岛素及CVD风险,加用孕激素削弱脂质效应,微粒化孕酮削弱最小。
  • 经皮雌激素对凝血、炎症和血脂影响小于口服,观察性研究提示静脉血栓栓塞和卒中风险更低。
  • 激素临床效应未见一致剂量依赖性;HT不推荐用于CVD一级或二级预防。

核心结论

  • HT在绝经管理中仍有重要作用,但不推荐用于CVD一级或二级预防。
  • 不同制剂、剂量和给药途径的HT对心脏代谢标志物和临床CVD事件风险有不同影响。

研究设计与样本

  • 本文为小型综述,基于作者在绝经HT领域的知识,并补充PubMed检索。
  • 检索词包括「menopause hormone therapy」「transdermal」「estradiol」「conjugated estrogens」「bioidentical」「cardiovascular disease」「lipoproteins」「glucose」「progestogens」「low dose」。

主要发现

  • 口服无对抗雌激素对脂蛋白水平、血糖、胰岛素和CVD风险有有利影响。
  • 加用孕激素削弱脂质相关效应,削弱作用最小的孕激素是微粒化孕酮。
  • 经皮雌激素对凝血、炎症和血脂的影响小于口服雌激素。
  • 观察性研究提示经皮雌激素的静脉血栓栓塞和卒中风险低于口服雌激素。
  • 激素的临床效应未呈现一致的剂量依赖性。

临床怎么用

  • 绝经管理中选择HT时需考虑制剂、剂量和给药途径对心脏代谢标志物及CVD事件风险的不同影响。
  • 不将HT用于CVD的一级或二级预防。

局限性

  • 评估经皮及其他替代HT方案临床结局的长期试验有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery. METHODS: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy," "transdermal," "estradiol," "conjugated estrogens," "bioidentical," "cardiovascular disease," "lipoproteins," "glucose," "progestogens," "low dose." RESULTS: Available evidence indicates that oral unopposed estrogens have a favorable effect on lipoprotein levels, glycemia, insulin, and CVD risk; however, the addition of progestogens blunts the lipid-related effects. The progestogen with the smallest attenuating effect is micronized progesterone. Transdermal estrogens have less effect on coagulation, inflammation, and lipids than oral estrogens and observational studies suggest they pose a lower risk of venous thromboembolism and stroke than oral estrogens. Clinical effects of hormones were not consistently dose dependent. CONCLUSIONS: Although HT continues to have an important role in menopause management, it is not recommended for primary or secondary CVD prevention. Different formulations, doses, and routes of delivery of HT have different effects on cardiometabolic markers and risks of clinical CVD events. However, long-term trials evaluating clinical outcomes with transdermal and other alternate HT regimens are limited.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shufelt CL, Manson JE. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. J Clin Endocrinol Metab. 2021. PMID: 33506261. doi:10.1210/clinem/dgab042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。